HCV Medications 2026: Costs, Cure Rates & Free Options

Hepatitis C is now a curable disease. Modern HCV medications — a group of oral drugs called direct-acting antivirals (DAAs) — clear the virus in more than 95% of people, usually within 8 to 12 weeks and with few side effects. The challenge for most patients is no longer whether treatment works, but how to afford it: US list prices for a full course run from roughly $24,000 to $95,000.

SunnyPharma compiled this guide from the AASLD-IDSA HCV guidance, FDA prescribing information, and manufacturer assistance program rules to answer the two questions patients ask most: which HCV medications cure the infection, and how to get them free or low-cost in the United States. We cover every direct-acting antiviral, cure rates, side effects, what treatment actually costs, and the access pathways that bring many patients to $0. For decisions about your own treatment, your clinician is the right source of guidance.

What HCV Treatment Costs — and What Patients Actually Pay

The list price of hepatitis C treatment is among the highest of any short course of medication in the US. But list price and patient cost are two completely different numbers. The single most important thing to know is this: almost no one who needs HCV treatment has to pay the sticker price, and many pay nothing at all.

Free and low-cost HCV treatment pathways

Work through these in order. Most patients reach a $0 or near-$0 outcome through one of them.

• Manufacturer patient assistance (uninsured): AbbVie’s program provides Mavyret at no cost to qualifying uninsured patients. Gilead’s Support Path does the same for Epclusa and its authorized generic sofosbuvir/velpatasvir. Both generally cover patients with household income up to roughly 500% of the federal poverty level.
• Manufacturer copay assistance (commercially insured): If you have private insurance, manufacturer copay programs can cover most or all of your out-of-pocket cost. These cannot be used with Medicare or Medicaid.
• Generic sofosbuvir/velpatasvir: An authorized generic of Epclusa is sold in the US through Gilead’s subsidiary Asegua Therapeutics at a far lower list price than the brand. It is a first-choice pangenotypic regimen, not a second-tier substitute.
• Medicaid: Every state Medicaid program covers HCV direct-acting antivirals. Most states have removed the old prior-authorization barriers that once required advanced liver damage or documented sobriety before approving treatment.
• Ryan White / ADAP (for HIV/HCV co-infection): Patients living with both HIV and hepatitis C may be able to access HCV treatment through the AIDS Drug Assistance Program. Find your state program at nastad.org/adap-watch.
• 340B pricing: Federally Qualified Health Centers and Ryan White clinics may dispense HCV medications at deeply reduced 340B prices. Ask whether your clinic participates.

HCV Medications: The Direct-Acting Antiviral (DAA) List

Direct-acting antivirals are the standard of care for hepatitis C. They target specific proteins the virus needs to replicate, and combination tablets attack more than one target at once. The pangenotypic regimens — effective against all six HCV genotypes — are first-choice for most patients because they simplify treatment and remove the need to wait on genotype results.

The best medication for hep C: how the choice is made

There is no single best DAA. Your clinician selects a regimen using the AASLD-IDSA HCV guidance based on three main factors: your HCV genotype, whether you have cirrhosis, and whether you have been treated before. For most treatment-naive patients without cirrhosis, a pangenotypic regimen — Mavyret or Epclusa — is the straightforward choice, and Mavyret often allows a shorter 8-week course. Patients who have failed a prior DAA, or who have advanced liver disease or kidney disease, may need a specific regimen such as Vosevi or Zepatier.

HCV Cure Rates: What “Sustained Virologic Response” Means

Hepatitis C is one of the few chronic viral infections that can be genuinely cured. Direct-acting antivirals clear the virus in more than 95% of people who complete treatment — a result that holds across genotypes, across most stages of liver disease, and in patients who have failed older therapies.

Cure is measured by sustained virologic response at 12 weeks (SVR12): no detectable HCV in the blood 12 weeks after the last dose. Achieving SVR12 means the infection is gone and, in the large majority of cases, does not come back. One important caveat: being cured does not make you immune. Reinfection is possible through new exposure, so cure is not a substitute for prevention.

Curing hepatitis C also lowers the long-term risks the infection drives — cirrhosis, liver failure, and liver cancer — though patients with existing advanced liver damage still need ongoing monitoring after cure.

Side Effects of HCV Medications

Direct-acting antivirals are well tolerated, which is one of the largest improvements over older interferon-based treatment. Most patients complete a course with mild or no side effects and continue their normal daily activities throughout.

• Most common: headache and fatigue. These are usually mild and resolve after treatment ends.
• Less common: nausea, and occasionally trouble sleeping or diarrhea.
• When ribavirin is added (for some patients with advanced liver disease): anemia, insomnia, and additional gastrointestinal effects. Ribavirin also carries pregnancy-related precautions that your clinician will review.

New HCV Drugs and Treatment Developments 2026–2027

Because current direct-acting antivirals already cure more than 95% of patients, hepatitis C research has shifted away from new drug classes and toward closing the gap between a curable disease and the people who still aren’t reached. The most significant developments are about access and simplification.

• Test-and-treat models: Point-of-care HCV RNA testing that diagnoses and starts treatment in a single visit — reducing the number of people lost between a positive test and the start of a cure. This approach was reinforced in June 2025, when the FDA expanded Mavyret’s approval to cover acute hepatitis C (infection within the previous six months) for patients aged 3 and older — the first and only direct-acting antiviral approved to treat HCV at the time of diagnosis, rather than waiting for the infection to become chronic.
• Shorter pangenotypic courses: Continued work on minimizing treatment duration without lowering cure rates, making completion easier.
• An HCV vaccine: Still in early research. A preventive vaccine remains a long-term goal, since cure does not confer immunity and reinfection is possible.
• Elimination programs: Public health efforts in 2026 are focused on expanding access to existing curative DAAs to meet the World Health Organization’s 2030 hepatitis C elimination target.

HCV Cost Guides: Specific Medications and Pathways

This hub routes to in-depth guides on what specific hepatitis C medications cost and how to access them. Each guide walks through pricing, assistance programs, and the steps to reduce what you pay.

Frequently Asked Questions